Kupffer cell oxidant production is central to the mechanism of peroxisome proliferators
Open Access
- 1 January 1999
- journal article
- research article
- Published by Oxford University Press (OUP) in Carcinogenesis: Integrative Cancer Research
- Vol. 20 (1) , 27-33
- https://doi.org/10.1093/carcin/20.1.27
Abstract
Increased cell proliferation most likely plays a key role in peroxisome proliferator-induced liver cancer. Recently, Kupffer cells were shown to be responsible for Wy-14,643-induced cell proliferation. However, the mechanism by which peroxisome proliferators activate Kupffer cells is unknown. Since gut-derived endotoxin is a known activator of Kupffer cells, the hypothesis that it is involved was evaluated. Increased cell proliferation and peroxisome induction were unaffected by gut sterilization. Moreover, endotoxin was not detectable in portal blood following treatment with Wy-14,643. Therefore, it is concluded that gut-derived endotoxin is not responsible for Kupffer cell activation. To test the hypothesis that Kupffer cells are activated by Wy-14,643 directly, Kupffer cell superoxide production was measured following treatment in vitro. Wy-14,643 increased superoxide production in a dose-dependent manner (0.1 and 50 μM) with half-maximal stimulation at 2.5 μM. Diethylhexylphthalate (DEHP) and ethylhexanol did not increase superoxide production even at doses 50 times higher than Wy-14,643; however, monoethylhexylphthalate (MEHP) activated superoxide production as effectively as Wy-14,643 with half-maximal stimulation at 5 μM. Treatment with Wy-14,643 for 21 days caused a 2-fold increase in Kupffer cell superoxide production while DEHP did not. Pretreatment of Kupffer cells with staurosporine (0.01–10 pM) completely blocked generation of superoxide demonstrating that protein kinase C is required. Moreover, Wy-14,643 increased Kupffer cell protein kinase C activity 3-fold. Pretreatment of Kupffer cells with the amino acid glycine (0.01–3 mM), which blunts calcium signaling, inhibited Wy-14,643-stimulated superoxide production and increased protein kinase C activity completely. These data are consistent with the hypothesis that potent peroxisome proliferators (Wy-14,643 and MEHP) directly activate Kupffer cell production of oxidants via mechanisms involving protein kinase C. Further, peroxisome proliferator treatments that sustain elevated rates of cell proliferation (e.g. Wy-14,643) activate Kupffer cell superoxide production following long-term dietary treatment supporting the hypothesis that Kupffer cell-derived oxidants are involved in peroxisome proliferator-induced neoplasia.Keywords
This publication has 23 references indexed in Scilit:
- Dietary Glycine Prevents Increases in Hepatocyte Proliferation Caused by the Peroxisome Proliferator WY-14,643Chemical Research in Toxicology, 1997
- Peroxisomal Proliferators Inhibit Acyl CoA Synthetase and Stimulate Protein Kinase C in VivoToxicology and Applied Pharmacology, 1994
- Biologically active products of stimulated liver macrophages (Kupffer cells)European Journal of Biochemistry, 1990
- Oxidative DNA damage caused by persistent peroxisome proliferation: its role in hepatocarcinogenesisMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1989
- Potentiation of diacylglycerol-activated protein kinase C by acyl-coenzyme a thioesters of hypolipidaemic drugsBiochemical and Biophysical Research Communications, 1989
- Relationship of oxidative damage to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and Wy-14,643Carcinogenesis: Integrative Cancer Research, 1989
- Catalase‐dependent ethanol oxidation in perfused rat liverEuropean Journal of Biochemistry, 1988
- Differential inhibition of prostaglandin and superoxide production by dexamethasone in primary cultures of rat Kupffer cellsEuropean Journal of Biochemistry, 1986
- A Potential Second Messenger Role for Unsaturated Fatty Acids: Activation of Ca 2+ -Dependent Protein KinaseScience, 1984
- Carcinogenesis by Hepatic Peroxisome Proliferators: Evaluation of the Risk of Hypolipidemic Drugs and Industrial Plasticizers to HumansCRC Critical Reviews in Toxicology, 1983